Ventilator Associated Pneumonia (VAP) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Ventilator Associated Pneumonia (VAP) – Pipeline Review, H2 2017’, provides an overview of the Ventilator Associated Pneumonia (VAP) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ventilator Associated Pneumonia (VAP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ventilator Associated Pneumonia (VAP) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Ventilator Associated Pneumonia (VAP)

The report reviews pipeline therapeutics for Ventilator Associated Pneumonia (VAP) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Ventilator Associated Pneumonia (VAP) therapeutics and enlists all their major and minor projects

The report assesses Ventilator Associated Pneumonia (VAP) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Ventilator Associated Pneumonia (VAP)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Ventilator Associated Pneumonia (VAP)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Ventilator Associated Pneumonia (VAP) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Achaogen Inc

Adenium Biotech ApS

Aridis Pharmaceuticals LLC

AstraZeneca Plc

Bayer AG

Cardeas Pharma Corp

Destiny Pharma Ltd

Dong-A Socio Holdings Co Ltd

Lakewood-Amedex Inc

MedImmune LLC

Meiji Seika Pharma Co Ltd

Merck & Co Inc

Motif Bio Plc

Nabriva Therapeutics AG

Polyphor Ltd

Shionogi & Co Ltd

Tetraphase Pharmaceuticals Inc

The Medicines Company

Theravance Biopharma Inc

Wockhardt Ltd

Zavante Therapeutics Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Ventilator Associated Pneumonia (VAP) - Overview 6

Ventilator Associated Pneumonia (VAP) - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Products under Development by Companies 11

Ventilator Associated Pneumonia (VAP) - Therapeutics Assessment 13

Assessment by Target 13

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Ventilator Associated Pneumonia (VAP) - Companies Involved in Therapeutics Development 21

Achaogen Inc 21

Adenium Biotech ApS 21

Aridis Pharmaceuticals LLC 22

AstraZeneca Plc 22

Bayer AG 23

Cardeas Pharma Corp 23

Destiny Pharma Ltd 24

Dong-A Socio Holdings Co Ltd 24

Lakewood-Amedex Inc 25

MedImmune LLC 25

Meiji Seika Pharma Co Ltd 26

Merck & Co Inc 26

Motif Bio Plc 27

Nabriva Therapeutics AG 27

Polyphor Ltd 28

Shionogi & Co Ltd 28

Tetraphase Pharmaceuticals Inc 29

The Medicines Company 29

Theravance Biopharma Inc 30

Wockhardt Ltd 30

Zavante Therapeutics Inc 31

Ventilator Associated Pneumonia (VAP) - Drug Profiles 32

(amikacin sulfate + fosfomycin) - Drug Profile 32

(avibactam + ceftazidime) - Drug Profile 34

(avibactam sodium + aztreonam lysine) - Drug Profile 39

(cefepime + zidebactam) - Drug Profile 41

(ceftolozane sulfate + tazobactam sodium) - Drug Profile 42

(cilastatin sodium + imipenem + relebactam) - Drug Profile 47

(meropenem+ vaborbactam) - Drug Profile 49

AA-139 - Drug Profile 53

Aerucin - Drug Profile 54

amikacin sulfate - Drug Profile 56

arbekacin - Drug Profile 58

ASN-100 - Drug Profile 59

cefiderocol - Drug Profile 62

EBX-004 - Drug Profile 66

eravacycline - Drug Profile 67

exeporfinium chloride - Drug Profile 74

fosfomycin tromethamine - Drug Profile 76

iclaprim mesylate - Drug Profile 79

lefamulin acetate - Drug Profile 84

Mul-1867 - Drug Profile 89

murepavadin - Drug Profile 91

Nu-2 - Drug Profile 93

Nu-3 - Drug Profile 94

Panaecin - Drug Profile 96

panobacumab - Drug Profile 97

plazomicin sulfate - Drug Profile 99

POL-7001 - Drug Profile 107

Qn-2251 - Drug Profile 108

sodium hypochlorite - Drug Profile 109

suvratoxumab - Drug Profile 110

tedizolid phosphate - Drug Profile 111

telavancin hydrochloride - Drug Profile 119

tosatoxumab - Drug Profile 124

Viritron VDX - Drug Profile 126

Ventilator Associated Pneumonia (VAP) - Dormant Projects 127

Ventilator Associated Pneumonia (VAP) - Discontinued Products 128

Ventilator Associated Pneumonia (VAP) - Product Development Milestones 129

Featured News & Press Releases 129

Appendix 139

Methodology 139

Coverage 139

Secondary Research 139

Primary Research 139

Expert Panel Validation 139

Contact Us 139

Disclaimer 140

List of Tables

List of Tables

Number of Products under Development for Ventilator Associated Pneumonia (VAP), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by Achaogen Inc, H2 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by Adenium Biotech ApS, H2 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by Aridis Pharmaceuticals LLC, H2 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by AstraZeneca Plc, H2 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by Bayer AG, H2 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by Cardeas Pharma Corp, H2 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by Destiny Pharma Ltd, H2 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by Dong-A Socio Holdings Co Ltd, H2 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by Lakewood-Amedex Inc, H2 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by MedImmune LLC, H2 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by Meiji Seika Pharma Co Ltd, H2 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by Merck & Co Inc, H2 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by Motif Bio Plc, H2 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by Nabriva Therapeutics AG, H2 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by Polyphor Ltd, H2 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by Shionogi & Co Ltd, H2 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by Tetraphase Pharmaceuticals Inc, H2 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by The Medicines Company, H2 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by Theravance Biopharma Inc, H2 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by Wockhardt Ltd, H2 2017

Ventilator Associated Pneumonia (VAP) – Pipeline by Zavante Therapeutics Inc, H2 2017

Ventilator Associated Pneumonia (VAP) – Dormant Projects, H2 2017

Ventilator Associated Pneumonia (VAP) – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Ventilator Associated Pneumonia (VAP), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Top 10 Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports